HomeBUSINESS
BUSINESS

1st Patient Dosed in PIII Enfortumab Vedotin Study: Astellas/Seattle Genetics
(Jul.11.2018)

Astellas Pharma and Seattle Genetics said on July 9 that the first patient has been dosed in a global PIII study evaluating their antibody drug conjugate (ADC) enfortumab vedotin in patients with previously treated urothelial cancer, the most common type of bladder cancer ...
(LOG IN FOR FULL STORY)